Immunoconcept India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.93 Cr
as on 17-07-2024
- Satisfied Charges ₹ 2.65 Cr
as on 17-07-2024
- Revenue 31.68%
(FY 2023)
- Profit 463.18%
(FY 2023)
- Ebitda 17.73%
(FY 2023)
- Net Worth 154.98%
(FY 2023)
- Total Assets 40.91%
(FY 2023)
About Immunoconcept India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.93 Cr. The company has closed loans amounting to ₹2.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
Laxmi Dandona and Harendra Kumar serve as directors at the Company.
- CIN/LLPIN
U74999DL2015PTC279473
- Company No.
279473
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Immunoconcept India Private Limited offer?
Immunoconcept India Private Limited offers a wide range of products and services, including Rapid Test Kit, Elisa Kits.
Who are the key members and board of directors at Immunoconcept India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Laxmi Dandona  | Director | 24-Apr-2015 | Current |
| Harendra Kumar | Director | 24-Apr-2015 | Current |
Financial Performance of Immunoconcept India.
Immunoconcept India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.68% increase. The company also saw a substantial improvement in profitability, with a 463.18% increase in profit. The company's net worth Soared by an impressive increase of 154.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunoconcept India?
In 2023, Immunoconcept India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Nov 2023 | ₹4.78 Cr | Open |
Axis Bank Limited Creation Date: 15 Dec 2021 | ₹1.15 Cr | Open |
Hdfc Bank Limited Creation Date: 23 Mar 2022 | ₹2.65 Cr | Satisfied |
How Many Employees Work at Immunoconcept India?
Unlock and access historical data on people associated with Immunoconcept India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunoconcept India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunoconcept India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
